Rebound of Psoriasis after Efalizumab Discontinuation, Despite Being on High-Dose Cyclosporine

September 2007 | Volume 6 | Issue 9 | Case Reports | 941 | Copyright © September 2007

Zahida Khan Maskatia BS, John Koo MD

Abstract
Psoriasis rebound after efalizumab discontinuation is well-documented in the literature. We report the case of a patient who experienced psoriasis rebound 2 months after efalizumab discontinuation, despite being on more than 5 mg/kg/day of cyclosporine. This case illustrates an instance where high doses of a very efficacious antipsoriasis therapy were not sufficient to prevent efalizumab-associated rebound. In addition to describing this case, we also propose a theoretical mechanism to explain how rebound after efalizumab discontinuation comes about.